HGSC harbors inactivating mutations in the tumor suppressor gene TP53 in >95% of the cases and germline or somatic BRCA1/BRCA2 gene variants, which are frequently associated with homologous recombination deficiency (HRD) in up to 22% of the cases (6). The gene discussed is BRCA1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.